Académique Documents
Professionnel Documents
Culture Documents
25
Introduction
At the beginning of the 21st century, the clinical application of platelet-rich plasma (PRP) was considered a
breakthrough in the stimulation and acceleration of bone and
soft tissue healing. Since then, its use has been predominantly
in maxillofacial surgery as an autologous additive to bone
grafts and soft tissue transplants, although other indications
such as chronic diabetic ulcers and some standard orthopedic
procedures have been suggested. This article will clarify the
rationale behind the clinical application of PRP by reviewing
the literature and outlining some of our own observations in
basic research.
Platelets and the growth factors they release are essential for
regulating the cellular events that follow tissue damage. They
adhere, aggregate, form a fibrin mesh, and subsequently release a large variety of growth factors and cytokines. At least
15 different factors are known to be contained within platelets [13], including platelet derived growth factor (PDRF-bb,
-ab und -aa isoforms), transforming growth factor-beta (TGFbeta, -beta1 and -beta2 isoforms), platelet factor 4 (PF4), interleukin 1 (IL-1), platelet-derived angiogenesis factor (PDAF),
vascular endothelial growth factor (VEGF), epidermal growth
factor (EGF), llatelet-derived endothelial growth factor
(PDEGF), epithelial cell growth factor (ECGF), insulin-like
growth factor (IGF), osteocalcin (Oc), osteonectin (On), fibrinogen (Fg), vitronectin (Vn), fibronectin (Fn) und thrombospontin-1 (TSP-1). The impact on bone and tissue regenera-
26
AODIALOGUE 1 | 07
we have demonstrated equal efficacy for freeze-thaw-activation of PRP [18]. In clinical practice PRP is used as a liquid,
made from 50100ml of full blood that quickly forms a gel
when applied with thrombin. Several companies have developed kits and devices for automatic preparation during surgical procedures.
Although the general concept seems plausible, controversy remains about whether PRP and other platelet preparations
meet the high expectations set by the clinical demands. For
the practitioner it appears very difficult to obtain information
on the actions and the possible risks of using platelet concentrates.
Clinical safety considerations
Clearly an autologous preparation does not bear the risks of transmissible diseases nor of
immunogenic reactions. If commercially available devices are
used, FDA approval will usually ensure that the preparation
Table 1
ies and small clinical trials on the clinical applications, knowledge about the underlying effects at the cellular level is limited. Nevertheless, PRP has been shown to stimulate cell
proliferation of osteoblasts and fibroblasts and to upregulate
osteocalcin in these cells [21, 22]. In a recent study by our
own group we demonstrated the differentiation of mesenchymal stem cells (MSC) into bone forming cells in the presence
Application
Type of study
Study design
Conclusion
Reference
Treatment of intra-
Comparative
[32]
bony defects
controlled clini-
cal study
Randomized
bony defects
clinical trial
(split mouth,
double masked)
grafts
Treatment of
Prospective case
infrabony defects
series
[33]
[34]
Prospective re-
view compared
to historical
results
cal results
[35]
was observed
Total ankle replace-
Comparative
ment
Study
[36]
ankle replacements
Treatment of mandib- Prospective
study
grafts alone
[37]
expert zone
of PRP [18]. An increase in growth and differentiation of PRPtreated periodontal ligament cells has been shown by two
groups [10, 23]. Further investigation revealed stimulation of
the mitogenic (ie, transforming) response to PRP in human
trabecular and rat bone marrow cells [24, 25]. Additionally,
we were able to demonstrate a strong effect on the expansion
of endothelial progenitor cells by platelet-released growth factors [26].
In vivo studies do not support the positive actions of PRP. In
fact, in one of the most recent investigations PRP decreased
the osteoinductivity of demineralized bone matrix in nude
mice [27]. Other researchers performed trials on various animals and reported no beneficial effect of using PRP for bone
healing [28] or suggest a low regenerative potential for its use
in combination with xenogenic bone grafts [29]. Some studies
also show effective augmentation of porous biomaterial in rats
[30] and sheep [31]. Careful analysis of these studies reveals
Table 2
27
Other applications
Application
Type of study
Study design
Conclusion
Reference
Treatment of chronic
Cohort study
[38]
ellbow tendinosis
Prospective
foot ulcers
randomized
controlled trial
Meta-analysis
without platelets
likely to heal
Treatment of diabetic
foot ulcers
Table 3
[39]
[40]
Device
Preparation time
Company
by manufacturer
GPS
12 min
Up to 8
20 min
Up to 7
Implant Innovations
Symphony II
15 min
Up to 6
DePuy
SmartPReP
15 min
Up to 9
Magellan
15 min
Up to 10
Medtronic
28
AODIALOGUE 1 | 07
Sebastian Lippross, MD
Bibliography
1 Eppley BL, Woodell JE, Higgins J (2004) Platelet quantification
and growth factor analysis from platelet-rich plasma: implications for
wound healing. Plast Reconstr Surg; 114: 15021508.
2 Weibrich G, Kleis WK, Hafner G, et al (2002) Growth factor levels
in platelet-rich plasma and correlations with donor age, sex, and
platelet count. J Craniomaxillofac Surg; 30:97102.
3 Yazawa M, Ogata H, Nakajima T, et al (2003) Basic studies on the
clinical applications of platelet-rich plasma. Cell Transplant; 12:509
518.
4 Bostrom MP, Saleh KJ, Einhorn TA (1999) Osteoinductive growth
factors in preclinical fracture and long bone defects models. Orthop
Clin North Am; 30:647658.
5 Boyan BD, Ranly DM, Schwartz Z (2006) Use of growth factors to
modify osteoinductivity of demineralized bone allografts: lessons for
tissue engineering of bone. Dent Clin North Am; 50:21728, viii.
6 Einhorn TA (1995) Enhancement of fracture-healing. J Bone Joint
Surg Am; 77:940956.
7 Glowacki J (1998) Angiogenesis in fracture repair. Clin Orthop Relat
Res; S82S89.
8 Laurencin CT, Ambrosio AM, Borden MD, et al (1999) Tissue
engineering: orthopedic applications. Annu Rev Biomed Eng; 1:1946.
9 Logeart-Avramoglou D, Anagnostou F, Bizios R, et al (2005)
Engineering bone: challenges and obstacles. J Cell Mol Med; 9:7284.
10 Lucarelli E, Beccheroni A, Donati D, et al (2003) Platelet-derived
growth factors enhance proliferation of human stromal stem cells.
Biomaterials; 24:30953100.
11 Mistry AS, Mikos AG (2005) Tissue engineering strategies for bone
regeneration. Adv Biochem Eng Biotechnol; 94:122.
12 Salgado AJ, Coutinho OP, Reis RL (2004) Bone tissue
engineering: state of the art and future trends. Macromol Biosci;
4:743765.
13 Street J, Bao M, deGuzman L, et al (2002) Vascular endothelial
growth factor stimulates bone repair by promoting angiogenesis and
bone turnover. Proc Natl Acad Sci USA; 99:96569661.
14 Anitua E, Andia I, Ardanza B, et al (2004) Autologous platelets
as a source of proteins for healing and tissue regeneration. Thromb
Haemost; 91:415.
15 Marx RE (2001) Platelet-rich plasma (PRP): what is PRP and what is
not PRP? Implant Dent; 10:225228.
16 Weibrich G, Kleis WK, Kunz-Kostomanolakis M, et al (2001)
Correlation of platelet concentration in platelet-rich plasma to the
extraction method, age, sex, and platelet count of the donor. Int J Oral
Maxillofac Implants; 16:693699.
17 Barthelmai W (1969) [Isolation of thrombocytes from small blood
volumes]. Klin Wochenschr; 47:266270.
18 Meury T KLSTAM. Effect of platelet-rich-plasma on bone marrow
stromal cell differentiation. [abstract]. ASBMR 26th annual meeting.
2007.
19 Cmolik BL, Spero JA, Magovern GJ, et al (1993) Redo cardiac
surgery: late bleeding complications from topical thrombin-induced
factor V deficiency. J Thorac Cardiovasc Surg; 105:222227.
expert zone
29